Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury

Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury

Hepatitis C virus (HCV)-induced inflammation contributes to progressive liver disease. The chemoattractant protein chemerin is associated with systemic inflammation. We hypothesized that chemerin is a biomarker that predicts the severity of liver disease in HCV patients. Furthermore, we investigated...

Full description

Bibliographic Details
Main Authors:	Georg Peschel, Jonathan Grimm, Karsten Gülow, Martina Müller, Christa Buechler, Kilian Weigand
Format:	Article
Language:	English
Published:	MDPI AG 2020-11-01
Series:	Diagnostics
Subjects:	HCV infection DAA body mass index MELD score liver fibrosis
Online Access:	https://www.mdpi.com/2075-4418/10/11/974

Similar Items

Gender-Specific Differences in Serum Sphingomyelin Species in Patients with Hepatitis C Virus Infection—Sphingomyelin Species Are Related to the Model of End-Stage Liver Disease (MELD) Score in Male Patients
by: Georg Peschel, et al.
Published: (2023-05-01)

Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy
by: Jonathan Grimm, et al.
Published: (2021-04-01)

HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV
by: Kilian Weigand, et al.
Published: (2022-12-01)

HCV eradication in people living with HIV: the final countdown?
by: A. De Vito, et al.
Published: (2021-02-01)

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection
by: Pinchera B, et al.
Published: (2023-02-01)

Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients
by: Mariantonietta Di Stefano, et al.
Published: (2021-09-01)

Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
by: Nathalie Alazard-Dany, et al.
Published: (2019-01-01)

B-type natriuretic peptide (BNP) in HCV-positive Egyptian patients: the impact of HCV eradication on plasma BNP levels
by: Ali Nada, et al.
Published: (2021-07-01)

Lymphocyte Landscape after Chronic <i>Hepatitis C Virus</i> (HCV) Cure: The New Normal
by: Alip Ghosh, et al.
Published: (2020-10-01)

The Role of RASs /RVs in the Current Management of HCV
by: Konstantinos Malandris, et al.
Published: (2021-10-01)

Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
by: Jingjing Wu, et al.
Published: (2019-01-01)

HCV cure for everyone or which challenges remain?
by: Jürgen Kurt Rockstroh
Published: (2015-04-01)

Cholestatic HCV Cryoglobulinemia: A New Clinical and Pathological Entity before and after Direct-Acting Antiviral Therapies—A Case-Control Study
by: Serena Ammendola, et al.
Published: (2024-01-01)

Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China
by: Jian Zhang, et al.
Published: (2019-07-01)

Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
by: Irene Pericot-Valverde, et al.
Published: (2020-12-01)

Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients
by: Reham M. Dawood, et al.
Published: (2022-08-01)

Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV
by: Zuzana Macek Jilkova, et al.
Published: (2021-12-01)

The relation between SNPs in the NME1 gene and response to sofosbuvir in Egyptian patients with chronic HCV
by: Mohamed AbdElrahman, et al.
Published: (2023-01-01)

LONG TERM FOLLOW UP AFTER HCV CURE WITH DIRECT ACTING ANTIVIRALS – REVIEW OF THE LITERATURE
by: Andreea Ruxandra Cazan, et al.
Published: (2018-12-01)

Long-Term Persistence of Mitochondrial DNA Instability among HCV-Cured People Who Inject Drugs
by: Mélusine Durand, et al.
Published: (2022-10-01)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
by: Ghweil AA, et al.
Published: (2019-04-01)

The Efficacy of Generic Daclatasvir-Sofosbuvir as Pan-Genotypic Regiment for Hepatitis C Virus (HCV) Infected Patients in Bandung Indonesia
by: Muhammad Begawan Bestari, et al.
Published: (2020-07-01)

Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection
by: Georg Peschel, et al.
Published: (2022-10-01)

Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols
by: Valeria Caputo, et al.
Published: (2020-07-01)

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
by: Vincenzo Messina, et al.
Published: (2020-12-01)

Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients
by: Beatriz Álvarez, et al.
Published: (2020-06-01)

Rising Lysophosphatidylcholine Levels Post-Hepatitis C Clearance
by: Georg Peschel, et al.
Published: (2024-01-01)

Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals
by: Nițescu Maria, et al.
Published: (2017-10-01)

Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) As a Biomarker for Lymphoid Malignancy with HCV Infection
by: Yutaka Tsutsumi, et al.
Published: (2023-05-01)

Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals
by: Devis Pascut, et al.
Published: (2019-11-01)

Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV
by: Violeta Lara-Aguilar, et al.
Published: (2023-06-01)

HCV Interplay With Mir34a: Implications in Hepatocellular Carcinoma
by: Ester Badami, et al.
Published: (2022-01-01)

Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project
by: Vincenzo Messina, et al.
Published: (2022-05-01)

Predictive plasma biomarkers of long-term increase in hepatic steatosis index after HCV eradication in HIV/HCV-coinfected patients
by: Rubén Martín-Escolano, et al.
Published: (2023-08-01)

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens
by: Ghias Un Nabi Tayyab, et al.
Published: (2020-04-01)

Critical role of triglycerides for adiponectin levels in hepatitis C: a joint study of human and HCV core transgenic mice
by: Ming-Ling Chang, et al.
Published: (2021-08-01)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
by: Filomena Morisco, et al.
Published: (2021-07-01)

Management Of Patients With Hepatitis B Virus Reactivation Post–DAA Treatment Of Chronic Hepatitis C Virus Infection In HCV–HBV Coinfected Patients With Pretreatment HBeAg Seroconversion And Early Degree Of Hepatic Fibrosis
by: Osman HA, et al.
Published: (2019-09-01)

Aggressive recurrence of Non-Hodgkin's Lymphoma after successful clearance of hepatitis C virus with direct acting antivirals
by: Dimitrios N. Samonakis, et al.
Published: (2021-03-01)

Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection
by: Chih-Hsun Yi, et al.
Published: (2022-08-01)